合作共赢 | 博腾与健翔达成战略合作，共筑多肽药物规模化生产新高地

Swipe Left for English News→

2026.3.22

近日，重庆博腾制药科技股份有限公司（简称“博腾”）与湖北健翔生物制药有限公司（简称“健翔”）共同宣布达成战略合作伙伴关系。双方将聚焦多肽药物领域，携手打造多肽药物研发至商业化生产的一站式服务体系，为全球医药客户提供高效、合规、规模化的多肽药物原料药及中间体定制化生产解决方案。

当前全球多肽药物行业蓬勃发展，创新管线持续扩容、商业化进程提速，市场对高标准规模化CDMO服务需求激增。博腾作为全球领先的CDMO企业，已搭建了一站式的多肽与寡核苷酸药物服务平台，在上海、重庆设有研发中心及GMP生产基地，具备多肽药物研发全周期规范化项目交付能力。健翔作为深圳市健元医药科技有限公司全资子公司，多年来专注布局多肽药物商业化生产领域，已完成大规模、高标准产能建设。公司严格遵循国际 cGMP 标准，现代化多肽原料药生产线已顺利通过美国 FDA、欧盟 EMA 及中国 NMPA 的多次核查，其中包含 10 条规模化生产线及中试生产线，具备承接大规模多肽原料药及中间体商业化生产的核心能力。

此次战略合作将整合多肽药物领域的研发资源、技术力量和生产能力，通过供应链资源共享和优势互补，形成紧密合作机制：

• 强强联合协同，释放规模效应：整合博腾前端研发及客户优势，与健翔后端商业化生产及合规优势，有望打通研发生产闭环，提升交付效率，强化博腾多肽CDMO核心竞争力。

• 一站式全链服务，全方位赋能客户：依托双方协同能力，为客户提供覆盖药物全生命周期的CMC解决方案，缩短产业化周期、降低研发成本，保障合规、稳定交付。

本次战略合作标志着双方在多肽药物领域的深度协同与强强联合，是博腾深化多肽领域布局、完善新分子能力的重要里程碑，亦是健翔以开放姿态拥抱生态共赢的新起点。未来，双方将秉持长期共赢的合作理念，持续深化产能协同、技术共享与项目合作，为全球客户提供更高效、可靠的多肽药物CMC一站式解决方案，携手让好药更早惠及大众。

健元医药湖北多肽原料药生产基地

博腾股份上海闵行研发中心

博腾股份上海奉贤生产基地

<左右滑动查看更多>

关于博腾股份

博腾股份（股票代码：300363）成立于2005年，主要为全球药企、生物科技公司、科研机构等提供从临床前研究到药品上市全生命周期所需的小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物的一站式服务解决方案，研发、生产、运营场地覆盖中国（重庆、上海、四川、江苏、江西、湖北）、美国、斯洛文尼亚、比利时、瑞士和丹麦等地。我们始终坚持以客户为中心，致力于为客户提供创新、可靠的全球化、端到端CDMO服务，让好药更早惠及大众。

关于湖北健翔生物制药有限公司

湖北健翔生物制药有限公司为深圳市健元医药科技有限公司的子公司，坐落于咸安经济开发区。其是健元医药多肽原料药生产的核心基地。厂区总面积超过54,000平方米，拥有先进的基础设施，专为高效合成与规模化生产而建，全面满足临床前、临床阶段及规模化商业批的市场需求。该基地集成了固相合成与液相合成两大技术体系，配备自动化制备色谱系统、连续纯化工艺，并预留了充足的扩展空间以满足未来发展需求。生产基地严格遵循国际CGMP标准，已成功通过美国FDA与中国NMPA的多次核查，赢得了全球制药及生物技术企业的广泛信赖。

2026.3.22

Porton Pharma Solutions Ltd. (“Porton”) and Hubei Jianxiang Bioscience Co., Ltd. (“Jianxiang”) jointly announced the launch of the strategic partnership. Focusing on the peptide drug sector, the two parties will join forces to build a one-stop service system covering peptide drug development through to commercial manufacturing, and provide efficient, regulatory-compliant and large-scale customized production solutions for peptide active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical clients worldwide.

The global peptide drug industry is enjoying robust development, with a growing pipeline of innovative drugs and accelerated commercialization progress, driving a sharp surge in market demand for high-standard and large-scale CDMO services.

As a leading global CDMO with deep expertise in complex drug modalities, Porton contributes its established one-stop service platform for peptide and oligonucleotide drug development and production. With state-of-the-art R&D centers and GMP-compliant manufacturing facilities in Shanghai and Chongqing, Porton brings proven end-to-end project delivery excellence, spanning early-stage research and process development through to full regulatory-compliant commercial manufacturing.

Jianxiang, a wholly owned subsidiary of JYMed Technology Co., Ltd., is a specialized manufacturer focused exclusively on commercial-scale peptide API production. The company has deployed substantial strategic investments to build large-scale, high-standard manufacturing infrastructure, featuring 10 commercial-scale production lines and dedicated pilot plants. All facilities are engineered and operated to meet the stringent cGMP standards established by the U.S. FDA, EMA and NMPA, providing the core large-scale production capacity to support global peptide API and intermediate supply.

This strategic partnership will integrate R&D resources, technical strength and manufacturing capabilities in the peptide drug field, and form a close cooperation mechanism through supply chain resource sharing and complementary advantages:

• Unlock Scale Effects: By integrating Porton’s advantages in front-end R&D and client resources with Jianxiang’s strengths in back-end mass production and regulatory compliance, the partnership is expected to build a closed R&D and manufacturing loop, improve delivery efficiency, and strengthen Porton’s core competitiveness in peptide CDMO services.

• Fully Integrated End-to-End CMC Solutions: Leveraging the synergistic capabilities of both parties, the partnership will provide clients with comprehensive CMC (Chemistry, Manufacturing and Controls) solutions covering the entire drug life cycle, shorten industrialization cycles, reduce total project costs, and ensure compliant and stable delivery of peptide drug substances.

This strategic partnership marks a deep synergy and strong alliance between the two parties in the peptide drug sector. It is a key milestone for Porton to deepen its layout in the peptide field and enhance its capabilities in novel molecule development, as well as a new starting point for Jianxiang to embrace ecosystem win-win with an open attitude.

Going forward, the two partners will uphold the philosophy of long-term win-win cooperation, continuously deepen capacity collaboration, technology sharing and project cooperation, and deliver more efficient and reliable one-stop peptide drug CMC solutions to global clients, working together to enable earlier access to good medicines.

JYMed's Hubei Peptide API Manufacturing Site

Porton Shanghai Minhang R&D Site

Porton Shanghai Fengxian Manufacturing Site

<View More>

About Porton

With over 4,200 employees and 18 operations and commercial offices across the US, EU, and China, Porton Pharma Solutions provides global pharmaceutical and biotech companies with innovative, reliable, and end-to-end process R&D and GMP manufacturing services across Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), as well as Advanced Therapy Medicinal Products.

We are committed to a customer-centric approach and have been recognized through awards by industry forums and global pharmaceutical and biotech companies for our process innovation, supply chain performance, and compliance with global quality and EHS standards. We constantly strive for excellence and enabling earlier access to good medicines.

About Hubei Jiansheng Bioscience Co., Ltd.

Situated in the Xian’an Economic Development Zone, Hubei Jianxiang Bioscience Co., Ltd. is the cornerstone of JYMed Peptide's large-scale peptide API production.Spanning a 300-acre campus with more than 54,000 m² of cutting-edge infrastructure, this site was built from the ground up to support complex peptide synthesis and high-volume production for both commercial and clinical markets.The facility integrates Solid Phase Peptide Synthesis (SPPS) and Liquid Phase Peptide Synthesis (LPPS) technologies, supported by automated preparative chromatography systems, continuous purification processes, and extensive capacity for future expansion.With strict adherence to international CGMP standards, the Hubei site has successfully passed multiple US FDA and NMPA audits, earning its reputation as a reliable partner for pharmaceutical and biotech companies worldwide.

(博腾股份 动态宝)